Eric Chatelain
Overview
Explore the profile of Eric Chatelain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saade U, de Boer J, Scandale I, Altcheh J, Pottel H, Chatelain E, et al.
Nat Commun
. 2024 Dec;
15(1):10530.
PMID: 39627222
Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected...
2.
Petit P, Touret F, Driouich J, Cochin M, Luciani L, Bernadin O, et al.
Heliyon
. 2024 May;
10(10):e30862.
PMID: 38803975
The SARS-CoV-2 pandemic has highlighted the need for broad-spectrum antiviral drugs to respond promptly to viral emergence. We conducted a preclinical study of molnupiravir (MOV) against SARS-CoV-2 to fully characterise...
3.
Hendrickx S, Feijens P, Escudie F, Chatelain E, Maes L, Caljon G
ACS Infect Dis
. 2024 May;
10(6):2101-2107.
PMID: 38733389
The bioluminescent BALB/c mouse model was used to evaluate the parasiticidal drug action kinetics of the reference drugs miltefosine, paromomycin, sodium stibogluconate, and liposomal amphotericin B. Infected mice were treated...
4.
Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, et al.
iScience
. 2024 Feb;
27(3):109049.
PMID: 38361624
Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses with...
5.
Bouzidi H, Driouich J, Klitting R, Bernadin O, Piorkowski G, Amaral R, et al.
Antiviral Res
. 2024 Jan;
222:105814.
PMID: 38272321
Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has shown the...
6.
Gonzalez S, Wall R, Thomas J, Braillard S, Brunori G, Camino Diaz I, et al.
Sci Transl Med
. 2023 Dec;
15(726):eadg8105.
PMID: 38091410
Chagas disease, caused by the protozoan parasite , affects millions of people in the Americas and across the world, leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ)...
7.
Braillard S, Keenan M, Breese K, Heppell J, Abbott M, Islam R, et al.
Sci Transl Med
. 2023 Dec;
15(726):eadh9902.
PMID: 38091406
New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required. Despite concerted efforts over the last several years, the number of new...
8.
Box H, Sharp J, Pennington S, Kijak E, Tatham L, Caygill C, et al.
J Antimicrob Chemother
. 2023 Nov;
79(1):172-178.
PMID: 37995258
Objectives: Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility...
9.
Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, et al.
bioRxiv
. 2023 Jul;
PMID: 37398307
Direct acting antivirals (DAAs) represent critical tools for combating SARS-CoV-2 variants of concern (VOCs) that evolve to escape spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence...
10.
Gabaldon-Figueira J, Martinez-Peinado N, Escabia E, Ros-Lucas A, Chatelain E, Scandale I, et al.
Res Rep Trop Med
. 2023 Jun;
14:1-19.
PMID: 37337597
Chagas disease is the most important protozoan infection in the Americas, and constitutes a significant public health concern throughout the world. Development of new medications against its etiologic agent, ,...